D-1095-2017 Class II Terminated

Recalled by Hetero USA Inc — Piscataway, NJ

FDA drug recall D-1095-2017 was initiated by Hetero USA Inc on Jul 20, 2017 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specification: single unknown impurity OOS 0.33% (Limit:NMT 0.20%W/W) at the three month stability point. The recall status is terminated (terminated Feb 27, 2019). Affected quantity: 5664 bottles.

Recall details

Product Type
Drugs
Report Date
Aug 23, 2017
Initiation Date
Jul 20, 2017
Termination Date
Feb 27, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
5664 bottles

Product description

Entecavir Tablets 0.5 mg, 30 tablets per container, Rx Only, Manufactured for: Camber Pharmaceuticals, Inc., Piscataway, NJ 08854. By: Hetero Labs Limited, Unit V, Polepally, Jadcherla, Mahaboob Nagar - 509 301, India. NDC 31722-833-30

Reason for recall

Failed Impurities/Degradation Specification: single unknown impurity OOS 0.33% (Limit:NMT 0.20%W/W) at the three month stability point.

Distribution pattern

NJ

Code information

Lot # ENT17008, Exp 01/2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1095-2017
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1095-2017. Report a data issue: hello@regdatalab.com.